fda compounding semaglutide crackdown september 2025 Non-Traditional Channels: The Compounded GLP-1 Market FDA Demurs on GLP-1 Compounding

Weight-loss drugs in the glucagon-like peptide-1 (GLP-1) class, such as Wegovy and Mounjaro, are being analyzed for their impact not only on body weight but also on psychological changes that can influence human relationships

Mansour, I

Development 120:11091121

Blood pressure: GLP-1 receptor agonists lower blood pressure on average in meta-analysis. Atherogenic lipoproteins (tirzepatide): Tirzepatide has been shown to improve lipoprotein biomarkers associated with insulin resistance and cardiovascular risk, including reductions in apoB and apoC-III , and changes in triglyceride-rich lipoprotein particles in clinical research. ApoB-containing lipoproteins (tirzepatide): In a study assessing mixed-meal/post-challenge lipid response, tirzepatide reduced fasting triglyceride-rich lipoproteins and overall apoB-containing lipoproteins . These findings align with common clinical search terms such as apoB , apoB-containing lipoproteins , atherogenic lipoproteins , and triglyceride-rich lipoproteins particularly for tirzepatide-related cardiometabolic effects., 4) They Affect Atherosclerotic Inflammation Imaging Signals (What We Know and Dont Know) Early mechanistic studies have evaluated whether semaglutide changes atherosclerotic plaque inflammation using advanced imaging (e.g., PET-MRI)